HippoFi, Inc. announced a partnership with ZIMMER BIOMET, aiming to redefine the spinal biologics landscape. This collaboration will harness the combined expertise of both companies to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi's biologic subsidiary, PUR Biologics. HippoFi/PUR has acquired the FDA 510(K) clearance for ActiveOrbTM technology, while also securing from Zimmer Biomet an exclusive global license to the underlying technology for the spine market.

Both entities have also engaged in a joint commercialization research agreement, with Zimmer Biomet overseeing the production of the spine-specific product under the PUR Biologics brand.